Lysosomal Therapeutics
Cambridge, Massachusetts, United States · Founded 2011
About Lysosomal Therapeutics
Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies.
Company Facts
- Founded: 2011
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $24.8M
- Funding stage: M&A
- Last round: Series A (Feb 2015)
- Website: lysosomaltx.com
- Phone: 617-913-0166
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/lysosomal-therapeutics-2534151 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.